Most common Mavenclad side effects, like headache, sore throat, and nausea, are short-lived and often resolve within days to weeks as your body adjusts to the medication. The more significant side effect, a drop in a type of white blood cell called lymphocytes, follows a longer and more predictable timeline that can stretch several months. Understanding both timelines helps you know what to expect during and after your treatment courses.
Common Side Effects Are Usually Brief
The most frequently reported side effects of Mavenclad include headache, cough, runny or stuffy nose, sneezing, and sore throat. These tend to appear around the time you take your tablets (each treatment course involves taking pills over a few days) and typically fade on their own without medical treatment. Stomach upset and vomiting are less common but can also occur during the dosing period.
These everyday side effects behave much like a mild cold or flu. They don’t tend to linger for weeks or require specific intervention. Your body adjusts to the medication relatively quickly, and for most people, these symptoms are a minor and temporary part of the treatment experience.
How Lymphocyte Counts Drop and Recover
The side effect with the longest timeline is lymphopenia, a reduction in lymphocytes, which are immune cells your body uses to fight infections. This isn’t an unexpected complication; it’s actually how Mavenclad works. The drug selectively reduces certain immune cells that drive multiple sclerosis activity. But this deliberate suppression means your immune system operates at reduced capacity for a stretch of time.
In clinical studies, 87% of patients experienced some degree of lymphocyte reduction. Your counts typically hit their lowest point about two to three months after you start each treatment course, and they drop lower with the second course in year two compared to the first. From there, recovery is gradual. In a study tracking lymphocyte dynamics, the median time for overall lymphocyte counts to return to the normal range was about 30 weeks after the last dose in year two (around week 84 of the treatment timeline). A specific subset of immune cells, CD4+ T cells, took longer, recovering to acceptable levels by roughly 43 weeks after that final dose.
One reassuring finding: CD8+ T cells, another important part of your immune defense, generally never dropped below the threshold considered clinically significant. So not all branches of your immune system are equally affected.
Severe Lymphopenia and Its Duration
Most patients experience a mild to moderate drop in lymphocyte counts, but some develop more severe reductions. About 26% of patients in clinical trials saw their lymphocyte counts fall below 500 cells per microliter, which is classified as a more serious (Grade 3) drop. Only about 1% experienced counts below 200 cells per microliter.
If you do develop severe lymphopenia, the median time to recover from Grade 3 back to a milder Grade 1 level was 28.1 weeks, or roughly seven months. By the end of year two in clinical trials, only 2% of patients still had counts below 500. So while severe lymphopenia can happen, most people recover from it within that seven-month window, and it rarely persists beyond the two-year treatment period.
When Infection Risk Is Highest
The period when your lymphocyte counts are at their lowest, roughly two to three months after each treatment course, is when you’re most vulnerable to infections. The risk of shingles (herpes zoster reactivation) is specifically elevated during periods when lymphocyte counts fall below 500 cells per microliter. This is why your doctor will monitor your blood counts regularly and may prescribe antiviral medication as a preventive measure if your counts dip very low.
This elevated infection risk isn’t permanent. It tracks directly with your lymphocyte recovery. As your counts climb back up over the following months, your susceptibility to opportunistic infections decreases accordingly. The practical window of heightened caution is roughly the first two to five months after each dosing course, though your individual blood work will guide exactly how long you need to be extra careful.
The Drug Itself Clears Quickly
One detail that surprises many people: cladribine, the active ingredient in Mavenclad, leaves your body fast. Its terminal half-life is approximately 24 hours, and the active compounds inside your cells have even shorter half-lives of 10 to 15 hours. Within a few days of taking your last tablet in a course, the drug itself is essentially gone from your system.
This is important context because it means the lasting side effects aren’t caused by the drug sitting in your body for months. Instead, cladribine does its work quickly by entering specific immune cells and disrupting them, and the lingering effects you feel are your immune system slowly rebuilding those cell populations. Think of it like a controlled reset: the button press is brief, but the reboot takes time.
Long-Term Safety Beyond Two Years
Mavenclad is designed as a short treatment course, two years total, with the expectation of lasting benefit. Four-year follow-up data presented in late 2024 from extension studies (MAGNIFY-MS and CLARIFY-MS) showed that the safety profile remained consistent with what was seen in the original clinical trials, with no new safety signals emerging over that longer period.
The one long-term consideration worth knowing about is a potential, though not definitively proven, link to malignancy. The prescribing information notes that treatment may increase cancer risk, which is why standard cancer screening is recommended for anyone who has taken Mavenclad. The risk of malignancy associated with taking additional courses beyond the standard two-year regimen has not been studied, which is one reason the drug is not typically given for more than two treatment years.